Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 North America Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 North America Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 North America Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. North America Opioid Use Disorder (OUD) Market by Drug Class
4.1 North America Buprenorphine Market by Country
4.2 North America Methadone Market by Country
4.3 North America Naltrexone Market by Country
Chapter 5. North America Opioid Use Disorder (OUD) Market by Route of Administration
5.1 North America Parenteral Market by Country
5.2 North America Oral Market by Country
Chapter 6. North America Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Retail Pharmacies & Stores Market by Country
6.3 North America Online Pharmacies Market by Country
Chapter 7. North America Opioid Use Disorder (OUD) Market by Country
7.1 US Opioid Use Disorder (OUD) Market
7.1.1 US Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 US Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 US Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Canada Opioid Use Disorder (OUD) Market
7.2.1 Canada Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 Canada Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 Canada Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 Mexico Opioid Use Disorder (OUD) Market
7.3.1 Mexico Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 Mexico Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 Rest of North America Opioid Use Disorder (OUD) Market
7.4.1 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
Unique Offerings 